delta-Cadinol is a sesquiterpene alcohol in the cadinane family that appears in hinoki and other wood- or bark-associated aromatic profiles in the AromaForge archive. The public evidence base is modest but usable: identity data are strong, fungal biosynthesis work directly characterizes a delta-cadinol synthase, and a few whole-oil studies report biological activity in oils where delta-cadinol is a major or notable component. The evidence does not support strong standalone wellness claims, so this record is best treated as a chemistry-first profile with clearly labeled mixture-level findings and alias overlap with cadin-1(10)-en-4beta-ol.
Chemical identity and composition
PubChem resolves delta-cadinol to CID 3084311 with formula C15H26O and synonym links including 1beta-Cadin-4-en-10-ol, torreyol, and CAS 19435-97-3. This means the present record substantially overlaps the archive's existing cadin-1(10)-en-4beta-ol synonym cluster rather than representing a completely separate evidence base. In local oil data, delta-cadinol is currently explicit in hinoki essential oil at 2.82%, while related cadinol naming variants also appear in other wood and sesquiterpene-rich profiles.
Aroma and practical use
- Use the recorded woody, balsamic, earthy, cedar-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2016 Natural Products and Bioprospecting paper identified and characterized a delta-cadinol synthase from the basidiomycete Boreostereum vibrans; the purified recombinant enzyme gave delta-cadinol as its principal product from farnesyl diphosphate.
A 2016 Natural Products and Bioprospecting paper identified and characterized a delta-cadinol synthase from the basidiomycete Boreostereum vibrans; the purified recombinant enzyme gave delta-cadinol as its principal product from farnesyl diphosphate.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
A 2010 Journal of Pharmacy and Pharmacology study reported that Kadsura longipedunculata stem-bark oil contained delta-cadinol at 5.11% and that the oil showed antimicrobial, moderate anti-inflammatory, trypanocidal, and some cytotoxic activity, but the isolated constituent was not tested as the sole active.
A 2010 Journal of Pharmacy and Pharmacology study reported that Kadsura longipedunculata stem-bark oil contained delta-cadinol at 5.11% and that the oil showed antimicrobial, moderate anti-inflammatory, trypanocidal, and some cytotoxic activity, but the isolated constituent was not tested as the sole active.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2023-to-2025 indexed Natural Product Research paper reported cadin-4-en-10-ol at 4.7% in Laportea bulbifera root essential oil, and that root oil showed bactericidal effects against several tested bacteria at 125 microL/mL, again providing only mixture-level context.
A 2023-to-2025 indexed Natural Product Research paper reported cadin-4-en-10-ol at 4.7% in Laportea bulbifera root essential oil, and that root oil showed bactericidal effects against several tested bacteria at 125 microL/mL, again providing only mixture-level context.
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA restriction, dermal maximum, or human tolerability study was verified for isolated delta-cadinol in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because the located biological findings are either biosynthetic or whole-oil studies, archive copy should avoid implying isolated delta-cadinol has proven antimicrobial, anti-inflammatory, or anticancer efficacy.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
delta cadinol synthase product formation
A 2016 full-text biosynthesis paper cloned a sesquiterpene synthase from Boreostereum vibrans and showed that the recombinant enzyme produced delta-cadinol as its principal product from farnesyl diphosphate.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
no human validated constituent mechanism
No human clinical mechanism or well-established isolated-molecule pharmacology for delta-cadinol was verified in this pass.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- Direct isolated pharmacology for delta-cadinol remains sparse in the reviewed public literature.
- The identity literature overlaps heavily with torreyol and cadin-1(10)-en-4beta-ol naming, so some source mapping is alias-based rather than unique to one archive spelling.
- Constituent-specific dermal, inhalation, reproductive, and chronic toxicology data were not verified in this pass.
- Worker c8 search (2026-07-13): no IFRA/RIFM or peer-reviewed dermal safety data specific to delta-cadinol (CAS 19435-97-3) located; only PubChem identity records and unrelated antimicrobial/biosynthesis papers found. Prior dermal_limit_pct:20 and sensitizing:true were unsupported placeholders and have been corrected to null/false.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.